- Conditions
- Cerebral Stroke
- Interventions
- CARET, CTI, Sham CARET, Sham CTI
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 2,795
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bipolar I Disorder, Depression
- Interventions
- Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2,726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
- Conditions
- Neoplasms
- Interventions
- Axitinib + Paclitaxel + Carboplatin (Cohort 1), Axitinib + Paclitaxel + Carboplatin (Cohort 2), Axitinib + Paclitaxel + Carboplatin (Cohort 3), Axitinib + Paclitaxel (Cohort 4), Axitinib + Docetaxel + Carboplatin (Cohort 4a), Axitinib + Docetaxel (Cohort 5), Axitinib + Capecitabine (Cohort 6), Axitinib + Capecitabine (Cohort 7), Axitinib + Gemcitabine + Cisplatin (Cohort 8), Axitinib + Pemetrexed + Cisplatin (Cohort 9)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 10
- States / cities
- Augusta, Georgia • Harvey, Illinois • Tinley Park, Illinois + 5 more
- Conditions
- Chronic Low Back Pain, Chronic Neck Pain
- Interventions
- Morphine, Duloxetine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV, Buprenorphine, Opioid Dependence
- Interventions
- Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced Solid Cancer, Metastatic Solid Cancer
- Interventions
- BI 3819026, Ezabenlimab (BI 754091)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Hackensack, New Jersey • New York, New York + 1 more
- Conditions
- HIV Infections
- Interventions
- ATV, Ritonavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 91 Days to 21 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more
- Conditions
- Pancreatic Cancer
- Interventions
- Masitinib, Placebo, Gemcitabine
- Drug
- Lead sponsor
- AB Science
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 12
- States / cities
- Norwich, Connecticut • Orlando, Florida • Atlanta, Georgia + 9 more
- Conditions
- Leukemia
- Interventions
- Lirilumab, Nivolumab, Azacitidine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Alzheimer's Disease
- Interventions
- RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 42
- States / cities
- Anaheim, California • Fullerton, California • Lomita, California + 36 more
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Overweight
- Interventions
- Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- G-CSF, Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Mesna, Methotrexate, Vincristine
- Biological · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Attention Deficit Disorder With Hyperactivity (ADHD)
- Interventions
- Heart Math Biofeedback Breathing Practices, Nutrition Counseling combined with Exercise Counseling
- Behavioral
- Lead sponsor
- Hoskinson Health and Wellness Clinic
- Industry
- Eligibility
- 7 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Gillette, Wyoming
- Conditions
- HIV/AIDS
- Interventions
- bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Standard initiation of antiretroviral therapy (ART)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Omaha, Nebraska
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 4
- States / cities
- Pasadena, California • San Francisco, California • St Louis, Missouri + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- Tilrekimig, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 12 more
- Conditions
- Hypertension
- Interventions
- Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more
- Conditions
- B-cell Lymphoma
- Interventions
- Parsaclisib, Rituximab, Bendamustine, Ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Indianapolis, Indiana • Las Vegas, Nevada + 4 more
- Conditions
- Asthma
- Interventions
- Fluticasone with salmeterol, Fluticasone HFA, Ipratropium HFA, Albuterol HFA
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • New York, New York
- Conditions
- Healthspan Improvement, Aging, Longevity
- Interventions
- Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
- Drug · Dietary Supplement · Behavioral
- Lead sponsor
- AgelessRx
- Industry
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Obesity, Adolescent
- Interventions
- Breakfast
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 13 Years to 21 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- HIV Infections
- Interventions
- Early Treatment with HAART, No treatment, HAART Treatment - standard care
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Advanced Solid Tumors
- Interventions
- TAS-102, Trifluridine
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas